1st GCC Oncology Updates Conference

Program: Three Parallel Tracks

11 September 2020
Virtual Conference

Room 1 METASTATIC HORMONE SENSITIVE PROSTATE CANCER (mHSPC) (4hrs 20′)

}

3 minutes

Welcome address and Introduction (pre-recorded address)
}

20 minutes

Plenary 1: Defining oligometastatic prostate cancer
}

20 minutes

Interactive discussion: Results of recent trials (HORRAD, CHAARTED, STAMPEDE, STOMP)
}

20 minutes

Interactive discussion: New developments in imaging techniques for metastatic disease (novel PET-CT radiotracers)
5 minutes – Break
}

20 minutes

Plenary 2: Standard androgen deprivation therapy (ADT) for mHSPC
}

20 minutes

Interactive discussion: Management of adverse effects: cardiovascular, bone and cognitive impairments
}

20 minutes

Interactive discussion: Intermittent versus continuous ADT
}

20 minutes

Satelite Symposium 1
5 minutes – Break
}

20 minutes

Plenary 3: Novel therapeutic approaches for mHSPC patients
}

20 minutes

Interactive discussion: Chemohormonal therapy for mHSPC – which patients benefit most?
}

20 minutes

Satelite Symposium 2
5 minutes – Break
}

20 minutes

Interactive discussion: Novel androgen synthesis inhibitors versus androgen receptor (nuclear translocation) inhibitors
}

20 minutes

Interactive discussion: Local treatment of the prostate – radiotherapy or radical prostatectomy?
}

20 minutes

Interactive discussion: Role of metastasis-directed therapy in mHSPC

Room 2 METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) (3hrs 20′) 

}

3 minutes

Welcome address and Introduction (pre-recorded address)
}

20 minutes

Plenary 1: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
}

20 minutes

Interactive discussion: Hopes and pitfalls of novel treatment options in mCRPC
}

20 minutes

Plenary 2: Genomic biomarkers in mCRPC
5 minutes – Break
}

20 minutes

Interactive discussion: Patient selection for PARP inhibitor therapy
}

20 minutes

Satelite Symposium 3
}

20 minutes

Interactive discussion: Pharmacogenomic biomarkers for chemotherapy in mCRPC
5 minutes – Break
}

20 minutes

Plenary 3: Novel theranostic approaches for mCRPC
}

20 minutes

Interactive discussion: Prostate-specific membrane antigen – targeted theranostics: the advent of targeted alpha therapy
}

20 minutes

Plenary 4: Tumor heterogeneity in prostate cancer
}

20 minutes

Interactive discussion: Towards novel biomarkers for guiding therapeutic strategies

Room 3 THE PROSTATE CANCER CHALLENGE (1hr 40′)

}

3 minutes

Welcome address and Introduction (pre-recorded address)
}

20 minutes

Interactive discussion: Managing Patients with Localised Prostatic Cancer
}

20 minutes

Interactive discussion: The Current Role Of Novel Androgen Receptor Signaling Inhibitors For Non Metastatic Castration-Resistant Prostate Cancer (Nmcrpc)
}

20 minutes

Satelite Symposium 4
}

40 minutes

Case Discussions with live Q&A and voting

Room 4 PRACTICAL SYMPOSIA (2hr)

}

3 minutes

Welcome address and Introduction (pre-recorded address)
}

40 minutes

Satelite Symposium 1
}

20 minutes

Satelite Symposium 2
}

20 minutes

Satelite Symposium 3
}

40 minutes

Satelite Symposium 4

Who should attend

This conference is designed for:

  • Urologists
  • Medical Oncologists
  • Radiation oncologists
  • Primary care physicians
  • Residents
  • Oher healthcare professionals involved in the diagnosis and management of prostate cancer

Why sponsor

  • Strengthen your position as a major supporter of clinical advancement in prostate cancer
  • Reach your target specialists
  • Create new and fortify existing relationships with key industry figures
  • Promote your products and company to delegates
  • Meet with peers and leaders in the industry and hold face-to-face meetings
  • Discuss current trends and challenges with the delegates and how your company can assist

This conference is Endorsed by

CME

Accreditation

This conference will acquire local and international Continuing Medical Education credit points which will be announced at a later date.